Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435508 | 0.82 | PNMT (0.31) | — | |
| SCHEMBL4436859 | 0.82 | NR1I2 (0.33) | — | |
| SCHEMBL7837454 | 0.72 | KDM4E (0.33) | — | |
| SCHEMBL15068507 | 0.72 | — | — | |
| SCHEMBL16566611 | 0.71 | — | — | |
| SCHEMBL4441329 | 0.71 | NR1I2 (0.33) | GABRA1GABRB2CYP1A2CYP3A4 | |
| SCHEMBL18283243 | 0.71 | NPC1 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3314980 | 0.70 | NUDT1 (0.41) | GABRA1GABRB2 | |
| SCHEMBL6468439 | 0.69 | TP53 (0.40) | GABRA1GABRB2MGLLCYP1A2CYP3A4 | |
| SCHEMBL14679607 | 0.68 | ALDH1A1 (0.39) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3082820-B1 | METHODS FOR MODULATING THE AMOUNT OF RNA TRANSCRIPTS | PTC THERAPEUTICS INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2809322-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013142236-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | GABRA1 939/4885GABRB2 160/4885MGLL 4239/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | GABRA1 1089/4885GABRB2 171/4885MGLL 3221/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | GABRA1 2091/4885GABRB2 1310/4885MGLL 2995/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | GABRA1 2180/4885GABRB2 1424/4885MGLL 2585/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | GABRA1 2180/4885GABRB2 1424/4885MGLL 2585/4885 |
| US-11382918-B2 | Methods for treating Huntington's Disease | HTT, HYPK, PARK7 | GABRA1 3009/4885GABRB2 1760/4885MGLL 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.